Conditions: headache · tirzepatide.
This is one of those things that everyone repeats and nobody derives.
This matters practically, not just academically, because it changes what I would do next.
Is the standard explanation correct, and if so, what is the evidence for it?
Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Hold rather than escalate while symptoms are active. Always.
edited 16 Aug 2026 by jo_vandeberg — added the method parameters
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
On the detail: titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Four half-lives between steps, minimum. Work it out for your agent.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.